Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Common Equity data on record, last reported at $654.3 million in Q4 2025.

  • For Q4 2025, Common Equity rose 107.49% year-over-year to $654.3 million; the TTM value through Dec 2025 reached $654.3 million, up 107.49%, while the annual FY2025 figure was $654.3 million, 107.49% up from the prior year.
  • Common Equity reached $654.3 million in Q4 2025 per OCUL's latest filing, up from $258.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $654.3 million in Q4 2025 and bottomed at $3.1 million in Q2 2023.
  • Average Common Equity over 5 years is $180.8 million, with a median of $87.7 million recorded in 2021.
  • Peak YoY movement for Common Equity: plummeted 95.31% in 2023, then surged 12135.02% in 2024.
  • A 5-year view of Common Equity shows it stood at $88.0 million in 2021, then crashed by 59.8% to $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then soared by 246.03% to $315.3 million in 2024, then surged by 107.49% to $654.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $654.3 million in Q4 2025, $258.2 million in Q3 2025, and $305.9 million in Q2 2025.